Expertise in
19
conditions

Dr. Natasha M. Tiffany

Hematology
St. Charles Health System Inc.
1541 NW Canal Blvd, 
Redmond, OR 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
19
conditions
St. Charles Health System Inc.
1541 NW Canal Blvd, 
Redmond, OR 

Overview

Natasha Tiffany is a Hematologist practicing medicine in Redmond, Oregon.

Dr. Tiffany is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Thrombocytopenia, Agranulocytosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Bone Marrow Aspiration.

She is actively involved in clinical research, participating in 8 clinical trials. Dr. Tiffany is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OR

Hospital Affiliations

St Charles Medical Center Prineville
Lake District Hospital
St Charles Madras
St Charles Medical Center - Bend

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
ATRIO Health
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

St. Charles Health System Inc.
1541 NW Canal Blvd, Redmond, OR 97756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2026
Intervention Type: Procedure, Other
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials
Similar Doctors
Expertise in
58
conditions
Dr. William G. Martin
Hematology | Oncology
Expertise in
58
conditions
Dr. William G. Martin
Hematology | Oncology
Referral may be required

St. Charles Cancer Center-Bend

2500 NE Neff Rd, 
Bend, OR 
 (16.2 miles away)
541-706-5800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Martin is a Hematologist and an Oncologist practicing medicine in Bend, Oregon. Dr. Martin is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Systemic Mastocytosis, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration. Dr. Martin is currently accepting new patients.

Expertise in
30
conditions
Dr. Richard D. Reed
Hematology | Oncology
Expertise in
30
conditions
Dr. Richard D. Reed
Hematology | Oncology
Referral may be required

St. Charles Cancer Center-Bend

2500 NE Neff Rd, 
Bend, OR 
 (16.2 miles away)
541-706-5800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Reed is a Hematologist and an Oncologist practicing medicine in Bend, Oregon. Dr. Reed is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Chronic Lymphocytic Leukemia (CLL). Dr. Reed is currently accepting new patients.

Expertise in
19
conditions
Dr. Todd W. Clover
Hematology | Oncology
Expertise in
19
conditions
Dr. Todd W. Clover
Hematology | Oncology
Referral may be required

St. Charles Cancer Center-Bend

2500 NE Neff Rd, 
Bend, OR 
 (16.2 miles away)
541-706-5800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Todd Clover is a Hematologist and an Oncologist practicing medicine in Bend, Oregon. Dr. Clover is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Clover is currently accepting new patients.

Frequently Asked Questions about Dr. Natasha M. Tiffany

How do I make an appointment with Dr. Natasha M. Tiffany?

You can book an appointment with Dr. Natasha M. Tiffany by calling their office at 541-706-5800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Natasha M. Tiffany a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Natasha M. Tiffany is classified as an Advanced expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Natasha M. Tiffany specialize in?

While Dr. Natasha M. Tiffany is a Hematology, they have specific expertise in Thrombocytopenia, Agranulocytosis, and Monoclonal Gammopathy of Undetermined Significance (MGUS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Natasha M. Tiffany accept my insurance?

Dr. Natasha M. Tiffany accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 541-706-5800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tiffany's expertise for a condition
ConditionClose
      View All 19 Advanced Conditions
      View All 56 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile